Genzyme General's stock fell more than 20 percent Thursday following the company's announcement after the market's close Wednesday that the company is lowering its 2002 second-quarter projections, as well as guidance for the year. (BioWorld Today)

Genzyme General's stock fell more than 20 percent Thursday following the company's announcement after the market's close Wednesday that the company is lowering its 2002 second-quarter projections, as well as guidance for the year. (BioWorld Today)

Less than a year ago, Eli Lilly and Co. and Isis Pharmaceuticals Inc. signed a deal for Isis' antisense technology worth as much as $400 million. On Tuesday the companies expanded that deal, opening it up to include specific gene targets for cancer and adding to its total value. (BioWorld Today)

Less than a year ago, Eli Lilly and Co. and Isis Pharmaceuticals Inc. signed a deal for Isis' antisense technology worth as much as $400 million. On Tuesday the companies expanded that deal, opening it up to include specific gene targets for cancer and adding to its total value. (BioWorld Today)